Daré Bioscience Past Earnings Performance
Past criteria checks 0/6
Daré Bioscience's earnings have been declining at an average annual rate of -19.1%, while the Pharmaceuticals industry saw earnings growing at 1.7% annually. Revenues have been growing at an average rate of 64% per year.
Key information
-19.1%
Earnings growth rate
26.1%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | 64.0% |
Return on equity | n/a |
Net Margin | -1,074.2% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
We're A Little Worried About Daré Bioscience's (NASDAQ:DARE) Cash Burn Rate
Nov 07We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully
Jul 21Is Daré Bioscience (NASDAQ:DARE) In A Good Position To Invest In Growth?
Mar 12Daré rises on positive data from early-to-mid-stage trial of intravaginal ring to treat menopause symptoms
Oct 17Daré Bioscience rises as company submits application to begin trial of non-hormonal contraceptive
Oct 10Dare Bioscience reports positive progress for cream for female sexual arousal disorder
Aug 29Daré Bioscience signs agreement with Organon for bacterial vaginosis therapy
Jun 30Will Daré Bioscience (NASDAQ:DARE) Spend Its Cash Wisely?
Apr 02Diving Back Into Daré Bioscience Again
Jan 07We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully
Nov 26Daré Bioscience's DARE-BV1 shows positive action in late-stage bacterial vaginosis study
Apr 26Diving Into Daré Bioscience
Jan 31Why Daré Bioscience, Inc. (NASDAQ:DARE) Could Be Worth Watching
Dec 22Dare Bioscience EPS misses by $0.06
Nov 12Revenue & Expenses BreakdownBeta
How Daré Bioscience makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 3 | -30 | 12 | 0 |
30 Sep 23 | 1 | -41 | 12 | 31 |
30 Jun 23 | 0 | -40 | 12 | 29 |
31 Mar 23 | 10 | -31 | 12 | 29 |
31 Dec 22 | 10 | -31 | 11 | 0 |
30 Sep 22 | 10 | -25 | 10 | 24 |
30 Jun 22 | 10 | -30 | 10 | 30 |
31 Mar 22 | 0 | -40 | 9 | 31 |
31 Dec 21 | 0 | -39 | 8 | 31 |
30 Sep 21 | 0 | -38 | 8 | 30 |
30 Jun 21 | 0 | -33 | 7 | 26 |
31 Mar 21 | 0 | -30 | 7 | 24 |
31 Dec 20 | 0 | -27 | 7 | 21 |
30 Sep 20 | 0 | -23 | 6 | 17 |
30 Jun 20 | 0 | -19 | 6 | 12 |
31 Mar 20 | 0 | -16 | 6 | 9 |
31 Dec 19 | 0 | -15 | 5 | 9 |
30 Sep 19 | 0 | -14 | 5 | 8 |
30 Jun 19 | 0 | -13 | 5 | 8 |
31 Mar 19 | 0 | -12 | 5 | 7 |
31 Dec 18 | 0 | -17 | 5 | 6 |
30 Sep 18 | 0 | -23 | 4 | 5 |
30 Jun 18 | 0 | -22 | 4 | 4 |
31 Mar 18 | 0 | -19 | 3 | 2 |
31 Dec 17 | 0 | -12 | 2 | 1 |
30 Sep 17 | 0 | -3 | 2 | 0 |
30 Jun 17 | 0 | -1 | 1 | 0 |
31 Mar 17 | 0 | -1 | 0 | 0 |
31 Dec 16 | 0 | -1 | 0 | 0 |
Quality Earnings: DARE is currently unprofitable.
Growing Profit Margin: DARE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DARE is unprofitable, and losses have increased over the past 5 years at a rate of 19.1% per year.
Accelerating Growth: Unable to compare DARE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DARE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-6.8%).
Return on Equity
High ROE: DARE's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.